Xenotransplantation
Xenotransplantation is moving forward through trials, one organ at a time. In May United Therapeutics received permission for an initial two-person heart study, which can expand only after its results are reviewed. Patient survival, graft function, infection risk and quality of life all matter, so no single twelve-month result will decide the question.
Research snapshot · updated Nov 12, 2026
State of the art (2026)
Pig-organ transplants have moved from one-off emergency cases into formal studies with several patients. eGenesis reports that Tim Andrews received its EGEN-2784 pig kidney on 25 January 2025 under an FDA-authorised expanded-access study and kept it for 271 days. United Therapeutics is running the EXPAND trial of its gene-edited pig kidney. No pig organ has marketing approval. The question now is whether groups of patients keep a working organ for a year or more without rejection or serious harm from the drugs that suppress the immune system.
Cluster trial cohorts replace single-patient compassionate-use
United Therapeutics UKidney FDA-cleared IND mid-2024 and eGenesis cluster trial IND filed 2025 mean 2026-2027 will produce the first multi-patient pig-kidney efficacy data (n=6-10 per trial). Single compassionate-use cases (Slayman, Looney, Andrews) generate news but not regulatory traction. Cluster cohorts with structured immunosuppression protocols generate FDA traction.
Kidney economics are decisive vs dialysis
$90-120K/year Medicare dialysis cost × decades of waitlist time vs $300-500K single-event xeno transplant with even 2-year graft survival = net savings to CMS within 3 years. Once any xeno protocol clears 12-month graft survival in a cluster cohort, ESRD reimbursement adapts. Heart xeno has weaker economics (pure life-extension) but stronger urgency (no dialysis equivalent).
10-gene-edit pigs are the new platform standard
eGenesis 10-edit pig (3-PERV-KO + 3 xenoantigen knockouts + 4 human transgenes for complement/coagulation/anti-inflammatory) plus Revivicor 10-GalSafe represent the new minimum viable genome. CRISPR multiplex base editing improvements 2024-2026 are the underlying enabler. Single-edit or 3-edit pigs from earlier programmes (XenoTransplant, Sernova) are obsolete.
Explore the deeper analysis in CanaryIQ
Explore what is covered below. These previews show the structure; log in to read the full analysis.
Signal stack
Evidence stacked leading → lagging
9 signals
Signal stack
Evidence stacked leading → lagging
Technology-native KPIs
Metrics that predict trajectory, tracked over time
4 tracked
Technology-native KPIs
Metrics that predict trajectory, tracked over time
Landscape map
Who builds what, and who depends on whom
50 players · 6 layers
Landscape map
Who builds what, and who depends on whom
Catalyst calendar
Dated events that will move the position
6 ahead
Catalyst calendar
Dated events that will move the position
Technology roadmap
Milestones on the path to maturity
8 milestones
Technology roadmap
Milestones on the path to maturity
Watchlists
Companies, people and papers, each with a condition for removing it
20 · 20
Watchlists
Companies, people and papers, each with a condition for removing it
Decision frameworks
What our view means for your job
Locked
Decision frameworks
What our view means for your job
Thesis changelog
When our view changed, and why
10 updates
Thesis changelog
When our view changed, and why
Change our mind
5 disconfirming conditions
You've read the verdict. The file is much deeper.
The full signal stack, technology-native KPIs tracked over time, the landscape of who depends on whom, the dated catalyst calendar, decision frameworks for every desk, live watchlists and a record of every time our view on Xenotransplantation has changed. All of it is in CanaryIQ.